|Bid||36.07 x 1000|
|Ask||36.09 x 1200|
|Day's Range||34.61 - 36.19|
|52 Week Range||20.05 - 39.10|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||143.47|
|Earnings Date||Nov 05, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.45|
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external search; Srini Ramanathan, Ph.D., group vice president, development sciences and San Francisco site head and Melanie Gloria, senior vice president, R&D operations, will report to Timothy Walbert, chairman, president and chief executive officer.
The New England Journal of Medicine published Phase 3 trial data for Horizon Therapeutics’ TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease.
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
Horizon Therapeutics today announced that the FDA has approved TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
Today we will run through one way of estimating the intrinsic value of Horizon Therapeutics Public Limited Company...
Jeffrey Hirsch -- editor of Stock Trader's Almanac -- select Global Brass and Copper Holdings as his favorite small cap stock for 2019. Following an April merger announcement, Global Brass shareholders received $44 per share in cash for a gain of roughly 75%. This year, Hirsch offers two risk-oriented ideas.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
Pharmaceutical stocks rose a single-digit percentage 2019, trailing their biotech brethren. Still, there are standout companies among the industry group.
Not all stocks are equal. Some will generate returns, while others will harvest losses. Some will soar magnificently, while others will crash and find it hard to reignite. The eternal question for the intrepid investor remains unchanged, though; which are the ones bound for fortune and, conversely, which are the ones to avoid.While nothing is certain, there are ways to help make the right decision. TipRanks’ Best Stocks to Buy tool tracks 8 key metrics and uses the results to score stocks accordingly. The tool displays the most compelling investments and gives them a Smart Score; from 1, down in the doldrums, all the way up to a “Perfect 10” at the peak of the summit.In this case, the data crunching tool recognized 3 healthcare stocks, which not only display Strong Buy status but also earned a “Perfect 10” Smart Score. Let’s take a closer look at the data at hand.Horizon Therapeutics (HZNP)In the rollercoaster world of healthcare so much hinges on the FDA’s approval or rejection of a new drug. Of course, it’s imperative to look at the bigger picture, and realize what these companies are trying to achieve in terms of their respective therapies. There is no doubt, though, that especially in this sector, the market reacts dramatically to both good and bad news.One such company looking forward to an FDA decision in the new year is biopharma Horizon Therapeutics. The company’s focus is on rare and rheumatic conditions, and a PDUFA date of March 8 will determine the future of Horizon’s teprotumumab drug, a treatment for active thyroid eye disease (TED). The disease can potentially lead to loss of vision and the drug could be the first treatment for TED to gain approval from the FDA.Clinical trials in both Phases 2 and 3 have displayed positive data, and an approval will add the treatment to a portfolio that the company thinks will generate between $1.28 billion and $1.31 billion in net sales in 2019.Piper Jaffray’s David Amsellem believes Horizon is "on the cusp of a seminal milestone." The analyst reveals in a note to clients that a recent physician survey indicated positive feedback for the drug and the approval of teprotumumab will lead to a "relatively high probability of wide adoption." Amsellem sees "ample room for significant further value creation” and thinks Horizon shares are set for multiple expansion.Unsurprisingly, then, Amsellem reiterated his Overweight rating and raised his price target from $36 to $49, which represents a potential upside of 36% from current levels. (To watch Amsellem’s track record, click here)The rest of the Street backs the Piper Jaffray analyst unanimously; all the analysts, 7 to be precise, tracked over the last 3 months, rate the biopharma a Buy; Therefore, Horizon has a Strong Buy consensus rating. The average price target of $40.57 indicates upside potential of 12%. (See Horizon stock analysis on TipRanks)Aravive Inc (ARAV)While the market has provided plentiful returns in 2019, not many have performed better than biotech Aravive. The micro-cap, which is focused on treatments for life threatening diseases, has added almost 300% to its share price throughout the year.Aravive’s lead candidate is AVB-500, a treatment for ovarian cancer and IgA nephropathy (kidney fibrosis). Recent data from a Phase 1b clinical trial of the drug in platinum-resistant recurrent ovarian cancer patients displayed positive results, with the study showing that women taking the drug exhibited higher rates of progression free survival. It is still early, though, and the trial was small, with only 31 patients.The company recently began a Phase IIa study of AVB-500 in IgA nephropathy patients, and Piper Jaffray’s Edward Tenthoff noted the predictive modeling shows that AVB-500 "should provide sufficient exposure for therapeutic efficacy and may support a pivotal trial start next year.”The 5-star analyst reiterated an Overweight rating, alongside a price target of $31. This implies upside potential of an excellent 125%. (To watch Tenthoff’s track record, click here)Further adding to the bull’s case is Cantor Fitzgerald’s Louise Chen, who believes “positive data readouts from Aravive's pipeline will drive shares higher.” Chen rates ARAV an Overweight alongside a $30 price target. (To watch Chen’s track record, click here)Over the last three months, two other analysts have joined the bullish pair with an opinion on Aravive. Both also rate the biotech a Buy, which grants Aravive a Strong Buy consensus rating. The average price target of $28.50 implies upside potential of 109%. (See Aravive stock analysis on TipRanks)DexCom Inc (DXCM)The synergy between technology and healthcare is constantly on the rise. The development of new tech enables treatment focused companies to break new ground and solve people’s day to day issues in ways not possible only a few years ago.This brings us to DexCom, the maker of the CGM (continuous glucose monitoring) system. The system enables diabetics to track and manage sugar levels by inserting a small sensor underneath the skin. The sensor measures glucose levels and through a transmitter which is fastened on top, wirelessly sends the data to a smart device.Statistics have shown that over 30 million people had diabetes in 2015 (over 9% of the population) and a further 84 million adults have had prediabetes, which if not treated, is a possible gateway to full blown diabetes. Although the numbers are alarming, they present significant market opportunity for Dexcom’s sugar monitoring products.The company has had an excellent 2019 and its share price skyrocketed over 80%. The recent third-quarter report helped continue the upward trend, with revenue of $396 million exhibiting growth of 49% from the previous year’s same period.Merrill Lynch’s Travis Steed thinks Dexcom’s 2019 performance is set to continue in the new year and rates the stock a “top idea for 2020.” The 5-star analyst highlights the company’s “competitive moat” and thinks DexCom is undervalued by the Street.Therefore, Steed reiterated a Buy rating on DXCM and raised his price target to $250 from $220. This conveys the analyst’s confidence in the company’s ability to add 14% to its share price over the next 12 months. (To watch Steed’s track record, click here)Steed is not alone in his bullish thesis, as 12 Buys and a single Hold bestow Strong Buy status on the groundbreaking glucose tracker. The average price target of $220.82, though, implies only small upside of 1%. This could mean that the analysts haven’t updated their models yet to reflect its 2019 gain. (See DexCom stock analysis on TipRanks)
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
Shares of Horizon Therapeutics gained 7% in premarket trading on Monday following a positive recommendation for its experimental eye drug from a Food and Drug Administration advisory committee on Friday. The committee voted 12-0 in favor of the FDA approving teprotumumab as a treatment for thyroid eye disease (TED), a rare autoimmune disorder. "Teprotumumab approval seems unquestionable, with discussions leading to a conclusion of allowing maximum access to finally give TED patients a real option," Stifel analysts wrote Dec. 16. The FDA is expected to decide whether to approve the biologic medication by March 8. The regulator is not required to follow the recommendation of the committee but it often does. Horizon's stock is up 54% year-to-date; the S&P 500 has gained 26%.
Horizon today announced the outcome of the FDA Advisory Committee meeting for teprotumumab for the treatment of thyroid eye disease (TED).
Horizon Therapeutics Plc shares were halted in premarket trade Friday, ahead of a U.S. Food and Drug Administration advisory committee meeting to discuss a treatment for Thyroid Eye Disease, a serious autoimmune disorder. The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet at 8 a.m. Eastern to discuss teprotumumab, an investigational medicine. The meeting is scheduled to run to 4 p.m. Thyroid Eye Disease often affects patients living with hyperthyroidism or Graves' disease, and can cause long-term damage to eyes, including proptosis, or eye bulging, strabismus, or misalignment of the eyes, and diplopia, or double vision, and in extreme cases can lead to blindness. Teprotumumab has received Priority Review, Orphan Drug and Fast Track and Breakthrough designations from the FDA. Horizon shares have gained 68% in 2019, while the S&P 500 has gained 26%.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that NASDAQ has halted trading of the Company’s common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 a.m. to 4 p.m. ET to discuss teprotumumab, an investigational medicine for the treatment of Thyroid Eye Disease (TED). Teprotumumab is an investigational medicine and its safety and efficacy have not been established.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference. Timothy Walbert, chairman, president and chief executive officer will present at 5 p.m. PT on Jan. 15, 2020.
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.